INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with ...

One of the main factors determining therapeutic antibodies’ half-life is the interaction between the antibody’s Fc region and the neonatal Fc receptor (FcRn). FcRn is central to the body’s ability to ...

The absence of TIPE2 in NK cells results in enhanced functional maturation, cytotoxicity, and IFN-γ production, indicating its potential as a checkpoint for NK cell immunotherapy.

MSK researchers learn that  immune cells are the unexpected source of a protein called FAS-ligand, which has undermined the cancer-fighting ability of engineered cell therapies. The team developed a ...

CIS, a negative regulator of IL-15 signaling, is upregulated by IL-15 in NK cells, and its absence enhances NK cell sensitivity to IL-15, proliferation, survival, and cytotoxicity against tumor cells.